Significantly lower risk is seen for mortality and progression. 28 studies from 26 independent teams in 11 countries show significant benefit.
Meta analysis using the most serious outcome reported shows 9% [3‑15%] lower risk. Early treatment is more effective than late treatment.
Studies to date do not show a significant benefit for mechanical ventilation and ICU admission. Benefit may be more likely without coadministered anticoagulants. The RECOVERY RCT shows 4% [-4‑11%] lower mortality for all patients, however when restricting to non-LMWH patients there was 17% [-4‑34%] improvement, comparable with the mortality results of all studies, 10% [4‑16%], and the 16% improvement in the REMAP-CAP RCT.
No treatment is 100% effective. Protocols combine safe and effective options with individual risk/benefit analysis and monitoring. Other treatments are more effective. All data and sources to reproduce this analysis are in the appendix.
4 other meta analyses show significant improvements with aspirin for mortality1-3, mechanical ventilation1, and progression4.
4 meta analyses show significant improvements with aspirin for mortality
1-3,
mechanical ventilation
1, and
progression
4.
Covid Analysis et al., Dec 2024, preprint, 1 author.
